Shandong Xinhua (00719) received the "Drug Supplement Application Approval Notice" for Rosuvastatin Calcium Tablets (20mg; 10mg)

SHANDONG XINHUA (00719) announced that recently the company received the approval notification from the National Medical Products Administration for the transfer of the marketing authorization application of rosuvastatin calcium tablets (20mg;10mg). The rosuvastatin calcium tablets (20mg;10mg) were approved by the National Medical Products Administration in January 2025, and Shandong Xinhua Pharmaceutical became the marketing authorization holder for this product. The market launch of this product will help enrich the company's product line of statin lipid-regulating drugs and enhance the company's overall competitive advantage.